HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rite Aid

This article was originally published in The Rose Sheet

Executive Summary

Former Interim CEO Timothy Noonan resigns from both the retailer and its board March 1. After 30 years with Rite Aid, Noonan intends to pursue other opportunities, the chain drug store says. Noonan was named interim CEO last October with the resignation of chief exec Martin Grass (1"The Rose Sheet" Oct. 25, 1999, p. 12). Robert Miller, Noonan's successor, was one of four former Fred Meyer execs appointed to top management positions in late 1999 (2"The Rose Sheet" Dec. 13, 1999, p. 11). Rite Aid Vice Chairman Franklin Brown resigns from the board effective May 29

You may also be interested in...



Rite Aid Heads West To Fill Executive Positions, Taps Fred Meyer Talent

Rite Aid's appointment of four former Fred Meyer executives to top management positions signifies a change in the drug store chain's West Coast business strategy.

Rite Aid Hopes For Greener Pastures After Cutting CEO Grass

Rite Aid will operate under a one-year turnaround deadline following the departure of CEO Martin Grass and the infusion of $300 mil. in financing from Leonard Green & Partners.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel